Clinical Trials on Risk Assessment in Czechia

Total 16 results

Institute for the Care of Mother and Child, Prague...
Coombe Women and Infants University Hospital

Completed

Does Routine Assessment of Gastric Residuals in Preterm Neonates Influence Time Taken to Reach Full Enteral Feeding? (GRASS)

Prematurity | Necrotizing Enterocolitis of Newborn | Sepsis Newborn | Gastric Residuals Assessment

Ireland, Czechia
Clinical Hospital Centre Zagreb
European Society of Hypertension

Unknown

Blood Pressure Control in ESH Excellence Centres (BP-CON)

White Coat Hypertension | Blood Pressure | Lifestyle Risk Reduction

Israel, Greece, Belgium, Germany, Armenia, Austria, Bulgaria, Croatia, Czechia, Estonia, Italy, Lebanon, Lithuania, Netherlands, Poland, Portugal, Romania, Serbia, Spain, Sweden, Ukraine, United Kingdom
The Medicines Company

Completed

Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol (ORION-11)

Risk Factor, Cardiovascular | Elevated Cholesterol | ASCVD

Germany, Czechia, Hungary, Poland, South Africa, Ukraine, United Kingdom
Medtronic BRC

Completed

Reveal® XT Performance Trial (XPECT)

Atrial Fibrillation | Risk of Cardiac Arrhythmias

Netherlands, Germany, Austria, Belgium, Canada, Czech Republic, Russian Federation, Slovakia
Sanofi
Bristol-Myers Squibb

Completed

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

Atrial Fibrillation | Vascular Risk

United States, France, Canada, Brazil, Poland, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Malaysia, Singapore, Taiwan, Belgium, Czech Republic, Mexico, Argentina, Denmark, Finland, Hungary, Norway, United... and more
Sanofi
Bristol-Myers Squibb

Terminated

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W)

Atrial Fibrillation | Vascular Risk

United States, France, Canada, Brazil, Poland, Russian Federation, Australia, Germany, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey, Malaysia, Singapore, Taiwan, Belgium, Czech Republic, Mexico, Denmark, Finland, H... and more
Ablynx, a Sanofi company

Completed

Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) Patients

Unstable Angina | Non ST Segment Elevation Myocardial Infarction (NSTEMI) | Stable Angina (Associated With High Risk PCI)

Poland, Belgium, Germany, Israel, Austria, Switzerland, Czechia
ECRI bv
University of Bern; European Cardiovascular Research Center; Terumo Medical Corporation and other collaborators

Completed

Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen (MASTER DAPT)

Coronary Artery Disease | PCI | High Bleeding Risk

Netherlands, France, United Kingdom, Australia, Singapore, Japan, Italy, Poland, Spain, Switzerland, Israel, Argentina, Austria, Bahrain, Bangladesh, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, India, Korea, Republic... and more
Bristol-Myers Squibb

Completed

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

High Risk Stage III Melanoma

Italy, Poland, United Kingdom, United States, Netherlands, Spain, Australia, France, Germany, Canada, Russian Federation, Belgium, Norway, Switzerland, Sweden, Finland, Austria, Denmark, Czechia
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

CANVAS - CANagliflozin cardioVascular Assessment Study (CANVAS)

Cardiovascular Diseases | Diabetes Mellitus, Type 2 | Risk Factors

United States, Australia, Poland, Ukraine, United Kingdom, Belgium, Germany, France, Spain, Argentina, Colombia, Israel, Mexico, India, Canada, Netherlands, Sweden, Malaysia, New Zealand, Estonia, Russian Federation, Hungary, Norway, ... and more
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2)

High-Risk Neuroblastoma | Patient With Insufficient Response Chemoimmunotherapy

France, Germany, Israel, Spain, United Kingdom, Belgium, Norway, Sweden, Finland, Australia, Czechia, Italy, Netherlands, Slovenia, Switzerland, Denmark, Greece, Lithuania, Slovakia
Novo Nordisk A/S
Duke Clinical Research Institute

Not yet recruiting

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack (ARTEMIS)

Cardiovascular Risk | Acute Myocardial Infarction (AMI)

Canada, China, United States, Germany, Spain, Korea, Republic of, Netherlands, Australia, Italy, Denmark, India, United Kingdom, Argentina, Turkey, Mexico, Malaysia, Czechia, Poland, Brazil, France, Japan, Bulgaria, Greece, Israel
AstraZeneca
The Cleveland Clinic; IQVIA RDS Inc.

Completed

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia (STRENGTH)

Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)

United States, Belgium, Italy, Netherlands, Denmark, Taiwan, Poland, Russian Federation, Korea, Republic of, Hungary, United Kingdom, China, New Zealand, Czechia, Australia, South Africa, Ukraine, Japan, Canada, Mexico, Lithuania, Estoni...
AstraZeneca
Bristol-Myers Squibb; Hadassah Medical Organization; The TIMI Study Group

Completed

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Diabetes Mellitus, Non-Insulin-Dependent | High Risk for Cardiovascular Event

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Thailand, Vietnam, Bulgaria, Korea, Republic of, Brazil, Philippines, Russian Federation, Turkey, Taiwan, Australia, Israel, South Africa, Germany, Japan, Czechia, H... and more
Bayer

Recruiting

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke (OCEANIC-STROKE)

Acute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic Attack

United States, Switzerland, Belgium, Sweden, Canada, Australia, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, Greece, Japan, Turkey, Netherlands, Romania, China, United Kingdom, Portugal, Italy, Brazil, France, Slovakia, ... and more
Novo Nordisk A/S

Recruiting

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation (ZEUS)

Inflammation | Chronic Kidney Disease | Cardiovascular Risk

Korea, Republic of, Italy, United States, Spain, China, Taiwan, Mexico, Netherlands, Latvia, Malaysia, Thailand, Hungary, Australia, Poland, South Africa, India, Canada, Portugal, Romania, United Kingdom, Bulgaria, Germany, Brazil, Sw... and more

Clinical Trials on Risk Assessment in Czechia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations